Israel's national hospital-at-home programme reports lower mortality than hospital admission

A retrospective national cohort study from Israel’s Clalit Health Services, a named, integrated payer-provider system, matched 3,335 hospital-at-home patients — treated for pneumonia, heart failure, urinary tract infection or cellulitis — 1:1 against general medical ward admissions. Thirty-day all-cause mortality was 5.8% for patients cared for at home against 9.1% for those admitted to hospital (adjusted odds ratio 0.6, 95% confidence interval 0.49–0.73); thirty-day readmission was 13% against 16% (adjusted odds ratio 0.8, 95% confidence interval 0.70–0.92). Eighty-four per cent of patients said they would choose hospital-at-home care again.

Audit/Data This is not UK evidence, and Israel’s health system, funding model and population differ enough that the absolute figures will not transfer directly. But it is a materially stronger evidence class than most hospital-at-home evidence available to this record to date: a large, matched, national cohort with a hard mortality endpoint, rather than a feasibility or satisfaction study. The mechanism is legible because the system is named and integrated: hospital-at-home is delivered here as a funded, protocolised alternative admission route, not a bolt-on pilot layered onto existing hospital-first pathways.

For any system evaluating or expanding a hospital-at-home or virtual ward offer, this is the evidence bar that an internationally comparable, funded, protocolised model is now setting — worth treating as a benchmark for what a UK evaluation should aim to demonstrate, rather than a result that can be assumed to apply without equivalent evaluation.